Noninvasive assessment of liver fibrosis and portal hypertension
Authors:
- 28 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 40 (3) , 148-155
Abstract
Purpose of review: The result of ongoing liver injury – and disease, regardless of cause – is fibrosis, and fibrosis appears to be a critically important result of ongoing injury. Further, in a number of different liver diseases, the presence of fibrosis has prognostic value. Therefore, the assessment of fibrosis is of critical clinical importance. Given the importance of fibrosis, there has been a rapid evolution in the use of noninvasive liver tests. This review highlights a number of the core principles surrounding. Recent findings: The use of noninvasive test has progressed rapidly over the last decade and data are rapidly accumulating. New terminology has been adapted by the American Association for the Study of Liver Disease (AASLD) for noninvasive assessment of liver disease and termed ‘NILDA’ (Non-Invasive Liver Disease Assessment). Blood based such as APRI and or FIB-4 and imaging tests such as liver stiffness measurement (LSM) have moderate to high degrees of accuracy for detection of advanced liver fibrosis (≥ F2) and even higher accuracy for detection of severe fibrosis (F4 or cirrhosis). NILDA are particularly effective at the ends of the liver disease spectrum. For example, a very low LSM (less than 7 kPa) essentially excludes significant fibrosis or portal hypertension, and a very high LSM (> 25 kPa) makes significant fibrosis with portal hypertension (cirrhosis) highly likely. Summary: NILDA are currently front and center in terms of assessment of the severity of liver disease. In all patients with known or suspected liver disease, noninvasive blood tests, including APRI and or FIB-4, should be the initial choice to assess the severity of liver fibrosis and/or portal hypertension. In most patients, these tests should be followed with imaging evaluation. The most commonly available imaging is LSM, which appears to be more accurate in predicting fibrosis severity, and is superior to blood tests in the assessment of portal hypertension. In situations in which there is diagnostic uncertainly, liver biopsy with or without HVPG remains an important consideration.Keywords
This publication has 28 references indexed in Scilit:
- Noninvasive Assessment of Liver Fibrosis in NAFLDClinical Gastroenterology and Hepatology, 2023
- Prediction of long‐term morbidity and mortality after liver transplantation using two‐dimensional shear wave elastography compared with liver biopsyLiver Transplantation, 2022
- Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant RecipientsClinical Gastroenterology and Hepatology, 2021
- Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy IndividualsClinical Gastroenterology and Hepatology, 2019
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLDJournal of Hepatology, 2017
- Risk of end‐stage liver disease, hepatocellular carcinoma, and liver‐related death by fibrosis stage in the hepatitis C Alaska CohortHepatology, 2017
- Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probeJournal of Hepatology, 2012
- Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosisJournal of Hepatology, 2009
- Liver biopsy†Hepatology, 2009